Randomised phase 2 study of pembrolizumab plus CC-486 versus pembrolizumab plus placebo in patients with previously treated advanced non-small cell lung cancer

Benjamin Levy(Sidney Kimmel Cancer Center), Giuseppe Giaccone(Georgetown University), Benjamin Besse(Université Paris-Sud), Enriqueta Felip(Vall d'Hebron Hospital Universitari), Marina Chiara Garassino(Fondazione IRCCS Istituto Nazionale dei Tumori), M. Dómine Gómez(Hospital Universitario Fundación Jiménez Díaz), Pilar Garrido(Instituto Ramón y Cajal de Investigación Sanitaria), Bilal Piperdi(Merck & Co., Inc., Rahway, NJ, USA (United States)), Santiago Ponce-Aix(Hospital Universitario 12 De Octubre), Daniel L. Menezes, Kyle J. MacBeth, Alberto Risueño, Ruta Slepetis, Xiaoling Wu, Abderrahim Fandi, Luis Paz‐Ares(Universidad Complutense de Madrid)
European Journal of Cancer
January 14, 2019
Cited by 62

Abstract


Related Papers

No related papers found

Powered by citation graph analysis